RadichJP, DaiH, MaoM et al.. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A2006;103:2794–2799.
RadichJPDaiHMaoM. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006;103:2794–2799.
)| false
JamiesonCH, AillesLE, DyllaSJ et al.. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med2004;351:657–667.
JamiesonCHAillesLEDyllaSJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657–667.
)| false
KantarjianH, SawyersC, HochhausA et al.. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med2002;346:645–652.
KantarjianHSawyersCHochhausA. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
)| false
HochhausA, DrukerB, SawyersC et al.. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood2008;111:1039–1043.
HochhausADrukerBSawyersC. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008;111:1039–1043.
)| false
O’BrienSG, GuilhotF, LarsonRA et al.. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med2003;348:994–1004.
O’BrienSGGuilhotFLarsonRA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
)| false
O’BrienSG, GuilhotF, GoldmanJM et al.. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract]. Blood2008;112:Abstract 186.
O’BrienSGGuilhotFGoldmanJM. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract]. Blood 2008;112:Abstract 186.
)| false
RoyL, GuilhotJ, KrahnkeT et al.. Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood2006;108:1478–1484.
RoyLGuilhotJKrahnkeT. Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478–1484.
)| false
CortesJ, O’BrienS, QuintasA et al.. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer2004;100:2396–2402.
CortesJO’BrienSQuintasA. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004;100:2396–2402.
)| false
Quintas-CardamaA, KantarjianH, O’BrienS et al.. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer2004;100:2592–2597.
Quintas-CardamaAKantarjianHO’BrienS. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004;100:2592–2597.
)| false
HochhausA, KantarjianHM, BaccaraniM et al.. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood2007;109:2303–2309.
HochhausAKantarjianHMBaccaraniM. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303–2309.
)| false
MauroMJ, BaccaraniM, CervantesF et al.. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7009.
MauroMJBaccaraniMCervantesF. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 7009.
)| false
BaccaraniM, RostiG, SaglioG et al.. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood2008;112:Abstract 450.
BaccaraniMRostiGSaglioG. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood 2008;112:Abstract 450.
)| false
GuilhotF, ApperleyJ, KimDW et al.. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood2007;109:4143–4150.
GuilhotFApperleyJKimDW. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143–4150.
)| false
ApperleyJF, CortesJE, KimDW et al.. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol2009;27:3472–3479.
ApperleyJFCortesJEKimDW. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009;27:3472–3479.
)| false
KantarjianH, CortesJ, KimDW et al.. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood2009;113:6322–6329.
KantarjianHCortesJKimDW. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322–6329.
)| false
CortesJ, RousselotP, KimDW et al.. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood2007;109:3207–3213.
CortesJRousselotPKimDW. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207–3213.
)| false
CortesJ, KimDW, RaffouxE et al.. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia2008;22:2176–2183.
CortesJKimDWRaffouxE. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176–2183.
)| false
SaglioG, KantarjianHM, HochhausA et al.. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035 [abstract]. Blood2008;112:Abstract 3226.
SaglioGKantarjianHMHochhausA. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035 [abstract]. Blood 2008;112:Abstract 3226.
)| false
Quintas-CardamaA, KantarjianH, O’BrienS et al.. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol2007;25:3908–3914.
Quintas-CardamaAKantarjianHO’BrienS. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
)| false
ShahNP, KantarjianHM, KimDW et al.. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol2008;26:3204–3212.
ShahNPKantarjianHMKimDW. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
)| false
StoneRM, KimDW, KantarjianHM et al.. Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 7007.
StoneRMKimDWKantarjianHM. Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 7007.
)| false
CortesJ, O’BrienS, BorthakurG et al.. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood2008;112:Abstract 182.
CortesJO’BrienSBorthakurG. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood 2008;112:Abstract 182.
)| false
KantarjianHM, GilesF, GattermannN et al.. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood2007;110:3540–3546.
KantarjianHMGilesFGattermannN. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–3546.
)| false
KantarjianH, GilesF, BhallaK et al.. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 7029.
KantarjianHGilesFBhallaK. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 7029.
)| false
le CoutreP, OttmannOG, GilesF et al.. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood2008;111:1834–1839.
le CoutrePOttmannOGGilesF. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834–1839.
)| false
Le CoutrePD, GilesF, HochhausA et al.. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 7057.
Le CoutrePDGilesFHochhausA. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 7057.
)| false
GilesFJ, LarsonRA, KantarjianHM et al.. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7017.
GilesFJLarsonRAKantarjianHM. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 7017.
)| false
MartinelliG, CastagnettiF, PoerioA et al.. Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML WP [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 7074.
MartinelliGCastagnettiFPoerioA. Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML WP [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 7074.
)| false
AliR, OzkalemkasF, OzcelikT et al.. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML): outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res2005;29:971–973.
AliROzkalemkasFOzcelikT. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML): outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005;29:971–973.
)| false
SeshadriT, SeymourJF, McArthurGA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med2004;351:2134–2135.
SeshadriTSeymourJFMcArthurGA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004;351:2134–2135.
)| false
SeymourJF, GriggA, ReynoldsJ et al.. Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML [abstract]. Blood2006;108:Abstract 2147.
SeymourJFGriggAReynoldsJ. Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML [abstract]. Blood 2006;108:Abstract 2147.
)| false
CortesJ, O’BrienS, AultP et al.. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib [abstract]. Blood2008;112:Abstract 3230.
CortesJO’BrienSAultP. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib [abstract]. Blood 2008;112:Abstract 3230.
)| false
GuoJQ, WangJYG, ArlinghausRB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res1991;51:3048–3051.
GuoJQWangJYGArlinghausRB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 1991;51:3048–3051.
)| false
CortesJ, TalpazM, BeranM et al.. Philadelphia chromosome negative chronic myelogenous leukemia rearrangement of the breakpoint cluster region: long-term follow-up results. Cancer1995;75:464–470.
CortesJTalpazMBeranM. Philadelphia chromosome negative chronic myelogenous leukemia rearrangement of the breakpoint cluster region: long-term follow-up results. Cancer 1995;75:464–470.
)| false
LiptonJH, KhoroshkoN, GolenkovA et al.. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma2007;48:497–505.
LiptonJHKhoroshkoNGolenkovA. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007;48:497–505.
)| false
MichalletM, MaloiselF, DelainM et al.. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia2004;18:309–315.
MichalletMMaloiselFDelainM. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004;18:309–315.
)| false
CortesJ, BaccaraniM, GuilhotF et al.. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood2008;112:Abstract 335.
CortesJBaccaraniMGuilhotF. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood 2008;112:Abstract 335.
)| false
HughesTP, BranfordS, WhiteDL et al.. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood2008;112:3965–3973.
HughesTPBranfordSWhiteDL. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008;112:3965–3973.
)| false
CastagnettiF, PalandriF, AmabileM et al.. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood2009;113:3428–3434.
CastagnettiFPalandriFAmabileM. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 2009;113:3428–3434.
)| false
BaccaraniM, RostiG, CastagnettiF et al.. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood2009;113:4497–4504.
BaccaraniMRostiGCastagnettiF. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009;113:4497–4504.
)| false
Gambacorti-PasseriniC, ZucchettiM, RussoD et al.. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res2003;9:625–632.
Gambacorti-PasseriniCZucchettiMRussoD. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9:625–632.
)| false
PicardS, TitierK, EtienneG et al.. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood2007;109:3496–3499.
PicardSTitierKEtienneG. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496–3499.
)| false
LarsonRA, DrukerBJ, GuilhotF et al.. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood2008;111:4022–4028.
LarsonRADrukerBJGuilhotF. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022–4028.
)| false
AultP, KantarjianHM, BryanJ et al.. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML) [abstract]. Blood2008;112:Abstract 4255.
AultPKantarjianHMBryanJ. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML) [abstract]. Blood 2008;112:Abstract 4255.
)| false
ThomasJ, WangL, ClarkRE, PirmohamedM. Active transport of imatinib into and out of cells: implications for drug resistance. Blood2004;104:3739–3745.
ThomasJWangLClarkREPirmohamedM. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
)| false
WhiteDL, SaundersVA, DangP et al.. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood2007;110:4064–4072.
WhiteDLSaundersVADangP. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064–4072.
)| false
WhiteDL, SaundersVA, DangP et al.. CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study [abstract]. Blood2008;112:Abstract 3187.
WhiteDLSaundersVADangP. CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study [abstract]. Blood 2008;112:Abstract 3187.
)| false
GiannoudisA, DaviesA, LucasCM et al.. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood2008;112:3348–3354.
GiannoudisADaviesALucasCM. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348–3354.
)| false
WhiteDL, SaundersVA, DangP et al.. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood2006;108:697–704.
WhiteDLSaundersVADangP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.
)| false
BranfordS, RudzkiZ, WalshS et al.. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistant and mutation in the ATP phosphate-binding loop are associated with a poor prognosis. Blood2003;102:276–283.
BranfordSRudzkiZWalshS. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistant and mutation in the ATP phosphate-binding loop are associated with a poor prognosis. Blood 2003;102:276–283.
)| false
SoveriniS, MartinelliG, RostiG et al.. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol2005;23:4100–4109.
SoveriniSMartinelliGRostiG. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
)| false
WillisSG, LangeT, DemehriS et al.. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naïve patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood2005;106:2128–2137.
WillisSGLangeTDemehriS. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naïve patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128–2137.
)| false
le CoutreP, TassiE, Varella-GarciaM et al.. Induction of resistance to the abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood2000;95:1758–1766.
le CoutrePTassiEVarella-GarciaM. Induction of resistance to the abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758–1766.
)| false
MahonFX, DeiningerMW, SchultheisB et al.. Selection and characterization of BCR-ABL positive cells lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood2000;96:1070–1079.
MahonFXDeiningerMWSchultheisB. Selection and characterization of BCR-ABL positive cells lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070–1079.
)| false
WeisbergE, GriffinJD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood2000;95:3498–505.
WeisbergEGriffinJD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498–505.
)| false
GorreME, MohammedM, EllwoodK et al.. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science2001;293:876–880.
GorreMEMohammedMEllwoodK. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
)| false
NicoliniFE, CormS, LeQH et al.. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia2006;20:1061–1106.
NicoliniFECormSLeQH. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006;20:1061–1106.
)| false
JabbourE, KantarjianH, JonesD et al.. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood2008;112:53–55.
JabbourEKantarjianHJonesD. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53–55.
)| false
KhorashadJS, de LavalladeH, ApperleyJF et al.. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol2008;26:4806–4813.
KhorashadJSde LavalladeHApperleyJF. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806–4813.
)| false
JabbourE, KantarjianH, JonesD et al.. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia2006;20:1767–1773.
JabbourEKantarjianHJonesD. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767–1773.
)| false
O’DwyerME, MauroMJ, KurilikG et al.. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood2002;100:1628–1633.
O’DwyerMEMauroMJKurilikG. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002;100:1628–1633.
)| false
CortesJE, TalpazM, GilesF et al.. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood2003;101:3794–3800.
CortesJETalpazMGilesF. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794–3800.
)| false
O’DwyerME, MauroMJ, BlasdelC et al.. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood2004;103:451–455.
O’DwyerMEMauroMJBlasdelC. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451–455.
)| false
TerreC, EclacheV, RousselotP et al.. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia2004;18:1340–1346.
TerreCEclacheVRousselotP. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004;18:1340–1346.
)| false
MedinaJ, KantarjianH, TalpazM et al.. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer2003;98:1905–1911.
MedinaJKantarjianHTalpazM. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905–1911.
)| false
FeldmanE, NajfeldV, SchusterM et al.. The emergence of Ph-, trisomy-8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol2003;31:702–707.
FeldmanENajfeldVSchusterM. The emergence of Ph-, trisomy-8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702–707.
)| false
BummT, MullerC, Al-AliHK et al.. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood2003;101:1941–1949.
BummTMullerCAl-AliHK. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941–1949.
)| false
DeiningerMW, CortesJ, PaquetteR et al.. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer2007;110:1509–1519.
DeiningerMWCortesJPaquetteR. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110:1509–1519.
)| false
JabbourE, KantarjianHM, AbruzzoLV et al.. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood2007;110:2991–2995.
JabbourEKantarjianHMAbruzzoLV. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110:2991–2995.
)| false
KantarjianHM, TalpazM, O’BrienS et al.. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood2003;101:473–475.
KantarjianHMTalpazMO’BrienS. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473–475.
)| false
MarinD, GoldmanJM, OlavarriaE, ApperleyJF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood2003;102:2702–2704.
MarinDGoldmanJMOlavarriaEApperleyJF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102:2702–2704.
)| false
ZonderJA, PembertonP, BrandtH et al.. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res2003;9:2092–2097.
ZonderJAPembertonPBrandtH. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092–2097.
)| false
JabbourE, KantarjianHM, JonesD et al.. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood2009;113:2154–2160.
JabbourEKantarjianHMJonesD. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154–2160.
)| false
KantarjianHM, LarsonRA, GuilhotF et al.. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer2009;115:551–260.
KantarjianHMLarsonRAGuilhotF. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551–260.
)| false
KantarjianH, PasquiniR, HamerschlakN et al.. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood2007;109:5143–5150.
KantarjianHPasquiniRHamerschlakN. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143–5150.
)| false
RousselotPH, FaconT, PaquetteR et al.. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard-dose imatinib: 2-year follow-up data from START-R [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7012.
RousselotPHFaconTPaquetteR. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard-dose imatinib: 2-year follow-up data from START-R [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 7012.
)| false
MarinD, KaedaJS, AndreassonC et al.. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer2005;103:1850–1855.
MarinDKaedaJSAndreassonC. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850–1855.
)| false
Quintas-CardamaA, KantarjianH, Garcia-ManeroG et al.. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer2007;109:248–255.
Quintas-CardamaAKantarjianHGarcia-ManeroG. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248–255.
)| false
CortesJE, KhouryHJ, CormS et al.. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: data from an ongoing phase II/III trial [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 7008.
CortesJEKhouryHJCormS. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: data from an ongoing phase II/III trial [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 7008.
)| false
KantarjianH, SchifferC, JonesD, CortesJ. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood2008;111:1774–1780.
KantarjianHSchifferCJonesDCortesJ. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111:1774–1780.
)| false
MuhlmannJ, ThalerJ, HilbeW et al.. Fluorescent in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer1998;21:90–100.
MuhlmannJThalerJHilbeW. Fluorescent in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998;21:90–100.
)| false
LandstromA, TefferiA. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma2006;47:397–402.
LandstromATefferiA. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma 2006;47:397–402.
)| false
Douet-GuilbertN, MorelF, Le CharpentierT et al.. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res2004;24:2535–2539.
Douet-GuilbertNMorelFLe CharpentierT. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res 2004;24:2535–2539.
)| false
SeongDC, KantarjianHM, RoJY et al.. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood1995;86:2343–2349.
SeongDCKantarjianHMRoJY. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995;86:2343–2349.
)| false
DewaldGW, WyattWA, JuneauAL et al.. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood1998;91:3357–3365.
DewaldGWWyattWAJuneauAL. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357–3365.
)| false
de LavalladeH, ApperleyJF, KhorashadJS et al.. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol2008;26:3358–3363.
de LavalladeHApperleyJFKhorashadJS. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
)| false
Quintás-CardamaA, CortesJE, O’BrienS et al.. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer2009;115:2912–2921.
Quintás-CardamaACortesJEO’BrienS. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009;115:2912–2921.
)| false
KantarjianH, TalpazM, CortesJ et al.. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res2003;9:160–166.
KantarjianHTalpazMCortesJ. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160–166.
)| false
HughesTP, HochhausA, BranfordS et al.. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) [abstract]. Blood2008;112:Abstract 334.
HughesTPHochhausABranfordS. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) [abstract]. Blood 2008;112:Abstract 334.
)| false
PressRD, LoveZ, TronnesAA et al.. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate treated patients with CML. Blood2006;107:4250–4256.
PressRDLoveZTronnesAA. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate treated patients with CML. Blood 2006;107:4250–4256.
)| false
PressRD, GalderisiC, YangR et al.. A half-log Increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res2007;13:6136–6143.
PressRDGalderisiCYangR. A half-log Increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136–6143.
)| false
CortesJ, TalpazM, O’BrienS et al.. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res2005;11:3425–3432.
CortesJTalpazMO’BrienS. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425–3432.
)| false
IacobucciI, SaglioG, RostiG et al.. Achieving a major molecular response at the time of a complete cytogenetic response predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res2006;12:3037–3042.
IacobucciISaglioGRostiG. Achieving a major molecular response at the time of a complete cytogenetic response predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006;12:3037–3042.
)| false
MarinD, MilojkovicD, OlavarriaE et al.. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood2008;112:4437–4444.
MarinDMilojkovicDOlavarriaE. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437–4444.
)| false
BaccaraniM, SaglioG, GoldmanJ et al.. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood2006;108:1809–1820.
BaccaraniMSaglioGGoldmanJ. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
)| false
HughesT, DeiningerM, HochhausA et al.. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood2006;108:28–37.
HughesTDeiningerMHochhausA. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
)| false
BranfordS, CrossNC, HochhausA et al.. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia2006;20:1925–1930.
BranfordSCrossNCHochhausA. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925–1930.
)| false
DarkowT, HenkHJ, ThomasSK et al.. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics2007;25:481–496.
DarkowTHenkHJThomasSK. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481–496.
)| false
NoensL, van LierdeMA, De BockR et al.. Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood2009;113:5401–5411.
NoensLvan LierdeMADe BockR. Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401–5411.
)| false
KantarjianHM, ShanJ, JonesD et al.. Significance of rising levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in complete cytogenetic response (CGCR) [abstract]. Blood2008;112:Abstract 445.
KantarjianHMShanJJonesD. Significance of rising levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in complete cytogenetic response (CGCR) [abstract]. Blood 2008;112:Abstract 445.
)| false
BranfordS, RudzkiZ, ParkinsonI et al.. Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood2004;104:2926–2932.
BranfordSRudzkiZParkinsonI. Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926–2932.
)| false
RousselotP, HuguetF, ReaD et al.. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood2007;109:58–60.
RousselotPHuguetFReaD. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58–60.
)| false
MahonFX, HuguetF, GuilhotF et al.. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre << stop imatinib >> (STIM) study [abstract]. Blood2008;112:Abstract 187.
MahonFXHuguetFGuilhotF. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre << stop imatinib >> (STIM) study [abstract]. Blood 2008;112:Abstract 187.
)| false
RossDDM, GriggA, SchwarerA et al.. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early [abstract]. Blood2008;112:Abstract 1102.
RossDDMGriggASchwarerA. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early [abstract]. Blood 2008;112:Abstract 1102.
)| false
TamCS, KantarjianH, Garcia-ManeroG et al.. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood2008;112:516–518.
TamCSKantarjianHGarcia-ManeroG. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008;112:516–518.
)| false
BranfordS, LawrenceR, FletcherL et al.. The initial molecular response of chronic phase CML patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening [abstract]. Blood2008;112:Abstract 331.
BranfordSLawrenceRFletcherL. The initial molecular response of chronic phase CML patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening [abstract]. Blood 2008;112:Abstract 331.
)| false
MilojkovicD, BuaM, ApperleyJF et al.. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival [abstract]. Blood2008;112:Abstract 332.
MilojkovicDBuaMApperleyJF. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival [abstract]. Blood 2008;112:Abstract 332.
)| false
SavageDG, SzydloRM, ChaseA et al.. Bone marrow transplantation for chronic myeloid leukemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol1997;99:30–35.
SavageDGSzydloRMChaseA. Bone marrow transplantation for chronic myeloid leukemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997;99:30–35.
)| false
YanadaM, NaoeT. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. Leuk Lymphoma2006;47:1747–1753.
YanadaMNaoeT. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. Leuk Lymphoma 2006;47:1747–1753.
)| false
de LabartheA, RousselotP, Huguet-RigalF et al.. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood2007;109:1408–1413.
de LabartheARousselotPHuguet-RigalF. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109:1408–1413.
)| false
ThomasDA, FaderlS, CortesJ et al.. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood2004;103:4396–4407.
ThomasDAFaderlSCortesJ. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.
)| false
ThomasDA, KantarjianHM, CortesJE et al.. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7019.
ThomasDAKantarjianHMCortesJE. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 7019.
)| false
RavandiF, FaderlS, ThomasDA et al.. Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7020.
RavandiFFaderlSThomasDA. Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 7020.
)| false
DaviesSM, DeForTE, McGlavePB et al.. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med2001;110:339–346.
DaviesSMDeForTEMcGlavePB. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339–346.
)| false
HansenJA, GooleyTA, MartinPJ et al.. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med1998;338:962–968.
HansenJAGooleyTAMartinPJ. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962–968.
)| false
HorowitzMM, RowlingsPA, PasswegJR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant1996;17(Suppl 1):S5–6.
HorowitzMMRowlingsPAPasswegJR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(Suppl 1):S5–6.
)| false
OrR, ShapiraM, ResnickI. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood2003;101:441–445.
OrRShapiraMResnickI. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441–445.
)| false
CrawleyC, SzyldoR, LalancetteM et al.. Outcomes of reduced intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood2005;106:2969–2976.
CrawleyCSzyldoRLalancetteM. Outcomes of reduced intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969–2976.
)| false
GoldmanJ, SzydloR, HorowitzMM et al.. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood1993;82:2235–2238.
GoldmanJSzydloRHorowitzMM. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993;82:2235–2238.
)| false
BeelenDW, GraevenU, ElmaagacliAH et al.. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood1995;85:2981–2990.
BeelenDWGraevenUElmaagacliAH. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995;85:2981–2990.
)| false
MortonAJ, GooleyT, HansenJA et al.. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood1998;92:394–401.
MortonAJGooleyTHansenJA. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998;92:394–401.
)| false
AnderliniP, ShethS, HicksK et al.. Re: imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant2004;10:883–884.
AnderliniPShethSHicksK. Re: imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004;10:883–884.
)| false
OehlerVG, GooleyT, SnyderDS et al.. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood2007;109:1782–1789.
OehlerVGGooleyTSnyderDS. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:1782–1789.
)| false
LeeSJ, KukrejaM, WangT et al.. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood2008;112:3500–3507.
LeeSJKukrejaMWangT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008;112:3500–3507.
)| false
JabbourE, CortesJ, KantarjianH et al.. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer2007;110:340–344.
JabbourECortesJKantarjianH. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007;110:340–344.
)| false
BrecciaM, PalandriF, IoriAP et al.. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res2009; in press.
BrecciaMPalandriFIoriAP. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res 2009; in press.
)| false
KolbHJ, SchattenbergA, GoldmanJM et al.. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood1995;86:2041–2050.
KolbHJSchattenbergAGoldmanJM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood 1995;86:2041–2050.
)| false
LuznikL, FuchsEJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control2002;9:123–137.
LuznikLFuchsEJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123–137.
)| false
GilleeceMH, DazziF. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leuk Lymphoma2003;44:23–28.
GilleeceMHDazziF. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leuk Lymphoma 2003;44:23–28.
)| false
SimulaMP, MarktelS, FozzaC et al.. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia2007;21:943–948.
SimulaMPMarktelSFozzaC. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 2007;21:943–948.
)| false
KantarjianHM, O’BrienS, CortesJE et al.. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood2002;100:1590–1595.
KantarjianHMO’BrienSCortesJE. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:1590–1595.
)| false
OlavarriaE, OttmannOG, DeiningerM et al.. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia2003;17:1707–1712.
OlavarriaEOttmannOGDeiningerM. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:1707–1712.
)| false
HessG, BunjesD, SiegertW et al.. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol2005;23:7583–7593.
HessGBunjesDSiegertW. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:7583–7593.
)| false
CarpenterPA, SnyderDS, FlowersMED et al.. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood2007;109:2791–2793.
CarpenterPASnyderDSFlowersMED. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791–2793.
)| false
DeAngeloDJ, HochbergEP, AlyeaEP et al.. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res2004;10:5065–5071.
DeAngeloDJHochbergEPAlyeaEP. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004;10:5065–5071.
)| false
WeisserM, TischerJ, SchnittgerS et al.. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica2006;91:663–666.
WeisserMTischerJSchnittgerS. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006;91:663–666.
)| false
PorkkaK, KoskenvesaP, LundanT et al.. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood2008;112:1005–1012.
PorkkaKKoskenvesaPLundanT. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005–1012.
)| false
RadichJP, GehlyG, GooleyT et al.. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood1995;85:2632–2638.
RadichJPGehlyGGooleyT. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:2632–2638.
)| false
RadichJP, GooleyT, BryantE et al.. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood2001;98:1701–1707.
RadichJPGooleyTBryantE. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood 2001;98:1701–1707.
)| false
OlavarriaE, KanferE, SzydloR et al.. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood2001;97:1560–1565.
OlavarriaEKanferESzydloR. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97:1560–1565.
)| false
MackinnonS, BarnettL, HellerG. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant1996;17:643–647.
MackinnonSBarnettLHellerG. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996;17:643–647.
)| false
